Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We investigated the outcome for children and young people with Early T-precursor acute lymphoblastic leukaemia (ETP-ALL), a recently described poor prognosis sub-group of T-ALL, treated on a contemporary protocol, UKALL 2003. After a median follow-up of 4 years and 10 months, the ETP sub-group, representing 16% of T-ALL patients, had non-significantly inferior 5-year event-free survival (76·7% vs. 84·6%, P = 0·2) and overall survival (82·4% vs. 90·9%, P = 0·1), and a higher relapse rate (18·6% vs. 9·6%, P = 0·1) compared to typical T-ALL. ETP-ALL has an intermediate risk outcome, which does not warrant experimental treatment or first remission allogeneic transplant for the group universally.

Original publication

DOI

10.1111/bjh.12882

Type

Journal article

Journal

Br J Haematol

Publication Date

08/2014

Volume

166

Pages

421 - 424

Keywords

Early T-precursor, acute lymphoblastic leukaemia, child, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infant, Male, Neoplasm Staging, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Treatment Outcome, Young Adult